CytomX

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. 

CEO
Sean A. McCarthy
CEOSean A. McCarthy
Employees
69
Employees69
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2010
Founded2010
Employees
69
Employees69

CTMX Key Statistics

Market cap
821.15M
Market cap821.15M
Price-Earnings ratio
598.90
Price-Earnings ratio598.90
Dividend yield
Dividend yield
Average volume
16.56M
Average volume16.56M
High today
$5.71
High today$5.71
Low today
$4.56
Low today$4.56
Open price
$5.30
Open price$5.30
Volume
28.04M
Volume28.04M
52 Week high
$8.21
52 Week high$8.21
52 Week low
$0.40
52 Week low$0.40

Stock Snapshot

CytomX(CTMX) stock is priced at $4.83, giving the company a market capitalization of 821.15M. It carries a P/E multiple of 598.90.

During the trading session on 2026-03-18, CytomX(CTMX) shares reached a daily high of $5.71 and a low of $4.56. At a current price of $4.83, the stock is +5.8% higher than the low and still -15.5% under the high.

Trading activity shows a volume of 28.04M, compared to an average daily volume of 16.56M.

Over the past 52 weeks, CytomX(CTMX) stock has traded between a high of $8.21 and a low of $0.40.

Over the past 52 weeks, CytomX(CTMX) stock has traded between a high of $8.21 and a low of $0.40.

CTMX News

Benzinga 29m
Why Is CytomX Therapeutics Stock Falling On Wednesday?

On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares. Th...

Why Is CytomX Therapeutics Stock Falling On Wednesday?
TipRanks 1d
CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures

CytomX Therapeutics Inc. (CTMX) has disclosed a new risk, in the Regulation category. CytomX Therapeutics Inc. faces heightened uncertainty as rapidly evolving...

TipRanks 2d
CytomX Therapeutics announces $250M common stock offering

CytomX Therapeutics (CTMX) announced that it has commenced an underwritten public offering of $250M of shares of common stock and, in lieu of common stock to ce...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More CTMX News

TipRanks 2d
CytomX Therapeutics announces Phase 1 expansion data on varsetatug masetecan

CytomX Therapeutics (CTMX) announced Phase 1 expansion data for its EpCAM PROBODY(R) ADC, varsetatug masetecan in late-line metastatic CRC. The preliminary data...

Benzinga 3d
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16. Analysts expect the South San Fra...

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

People also own

Based on the portfolios of people who own CTMX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.